Probi announces new representative for Blis Board

ADMIN
Tue, Dec 20 2022 02:43 pm

20 December 2022

Probi announces new representative for Blis Board

Blis Technologies Limited (NZX:BLT) advises the appointment of Dr Jörn Andreas as a director of the company with effect from 1 January 2023. Dr Andreas will replace Tom Rönnlund who is retiring from the board following stepping down as CEO of Probi AB earlier this month.

Dr Andreas has been a director of Probi AB since 2019 and is CEO of the Cosmetic Ingredients Division at Symrise . He also has experience from both a previous assignment as board member (2014-2016) at Probi and his position as CFO of the company (2017-2018).

He has extensive international experience working at Symrise in France and USA in different finance and general management roles. Jörn has also worked for The Boston Consulting Group and Bayer AG in Germany.

The board has determined that Dr Andreas is not an independent director due to his role as a director of Probi AB, which is a substantial product holder of Blis Technologies. Dr Andreas will formally offer himself for re-election as director at the 2023 shareholders’ meeting.

Chairman Geoff Plunket said “We are delighted to have Jörn joining the board. Jörn has extensive commercial experience in senior executive and board roles that will complement our refocused strategy. His experience with both Probi and Symrise provides insight across a significant cross section of ingredient markets globally.”

I also wish to acknowledge the contribution Tom has made during his time on the board. He has provided valuable insights into the probiotic market and been pivotal in his role as Probi CEO in establishing a strong working relationship between the Blis and Probi teams.


Ends

For further information, please contact:

Geoff Plunket
Chair
+64 21 229 8886

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.


Announcement PDF


Markets News

NZ sharemarket up 0.4% after a2 Milk surge
Markets Market Close

NZ sharemarket up 0.4% after a2 Milk surge

The S&P/NZX 50 Index closed at 12,266.25, gaining 57.2 points or 0.47%.

Graham Skellern 14 Mar 2025
Markets

Goldman Sachs downgrades Fletcher Building to sell

Goldman Sach analysts have a 12-month target price of A$2.85 ($3.14).

Rebecca Howard 14 Mar 2025
Goldman Sachs downgrades Fletcher Building to sell
Primary Sector

Rayonier exits NZ with $1.2b forestry sale

An investment firm bought the stake, which included 116,145 hectares of forestry.

John Anthony 14 Mar 2025
Rayonier exits NZ with $1.2b forestry sale